DERMATOLOGY REFERRAL FORM P-Z



Phone (888) 370.1724 Fax (877) 645.7514 10004 S. 152nd St, Suite A, Omaha NE 68138

Patient Information	ation	PLEASE FAX	AX INSURANCE CARD (FRONT AND BACK)			Prescriber Information				
Last Name	First Name		DOB			Practice/Facility Name				
Address			•			Address				
City		State	ZIP			City	State	ZIP		
Phone		•	SSN			Prescriber Name		•		
Allergies			Latex Allergy	Yes N	No	Prescriber NPI				
Sex Male Female Weight (kg)			Height (ft,in)			Nurse/Key Contact	Phone/Pager			
Insurance Plan			Plan ID #			Fax	Email	il		
Diagnosis/Clin	ical Inf	ormation	PLEASE FAX CI	LINICAL AND LAB I	NFORMATI	ON				
	Yes	nspecified e disease: No	L40.5 Psoriat	TB test:/	'3.2 Hidrade	nitis Suppurativa Other: _				
Prescription In	formati	ion								
MEDICATION			OOSE/STRENGTI	H/DIRECTIONS FO	R USE		QTY	REFIL	LS	
Remicade®			Starter dose: 5	ōmg/kg (r	ng) IV at wee	eks 0, 2 and 6	QS	0		
Weightkg Biosimilars: Inflectra® Renflexis®	Vial		Maintenance dose: 5mg/kg(mg) IV every 8 weeks						_	
Siliq®	PFS		Starter dose: Inject 210mg SC on weeks 0, 1 and 2, inject 210mg SC every 2 weeks thereafter					mg/1.5ml 0		
	110		Maintenance dose: Inject 210mg SC every 2 weeks					mg/1.5ml	_	
Simponi®	SmartJect Autoinjector PFS		Inject 50mg SC once a month				1 x 50m	ng/0.5ml	_	
Stelara®			Starter dose: Inject 45mg SC on Day 1 (≤100 kg)					0		
Weightkg	PFS		Starter dose: Inject 90mg SC on Day 1 (>100 kg) Maintenance dose: Inject 45mg SC on Day 29 and every 12 weeks thereafter (≤100 kg)							
					•	nd every 12 weeks thereafter (≤10 nd every 12 weeks thereafter (>10		2 x 210mg/1.5ml 1 x 50mg/0.5ml 1 x 45mg/0.5ml		
Taltz®	Autoin PFS	njector				ek 0, then inject 80mg SC at week		day		
	Autoinjector		Starter dose: Inject 80mg SC at week 4 and every 2 weeks thereafter through week 10				ng/ml 0			
	Autoin	ijector				and every 4 weeks thereafter				
Tremfya®	PFS		Starter dose: Inject 100mg SC at week 0, then 100mg at w				s 2 x 100	img/ml 0		
	PFS		thereafter Maintenance described 400 at 400							
			Maintenance dose: Inject 100mg SC every 8 weeks				1 x 100	img/ml		
n order for a brand name prod	duct to be dis	spensed, the prescrib	per must handwrite "E	Brand Necessary" or "Bra	and Medically N	lecessary," or your state-specific required	I language to prohibit	substitution:		
PRESCRIBER MUST MA	NUALLY SI	GN - STAMP SIGN	NATURE, SIGNATL	JRE BY OTHER PERS	SONNEL AND	COMPUTER-GENERATED SIGNA	TURES WILL NOT	BE ACCEPTED		
	ON D==-:				DIODE	NICE AC MIDITEN (D - NI-+ O I	*i**a ′	data		
PRODUCT SUBSTITUTION authorize Amber Pharma		•	.	, ,		NSE AS WRITTEN/Do Not Subs insurance prior authorization proc		date) o, to release clinica	ı	

information via phone to the appropriate third party payer.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you. Amber Enterprises, Inc., dba Amber Pharmacy © 2017